Introduction
Multiple sclerosis (MS) is a neurological disorder that is best-characterized by the development of demyelinating lesions and, in some cases, axonal loss within the central nervous system (CNS). 1 An additional hallmark of disease is a compromise in the integrity of specialized endothelial cells separating the peripheral blood from the brain parenchyma collectively referred to as the blood-brain barrier (BBB). 2 These histological signs correlate with significant infiltration of leukocytes of the innate and adaptive immune system into the brain. Left untreated, this tissue dysfunction eventually leads to a progressive loss of neuromuscular function and a severely compromised quality of life. 1 Given the significant immune cell accumulation at sites of acute demyelination, the efficacy of MS drugs targeting the peripheral leukocyte compartment and numerous immune-related genetic polymorphisms associated with disease susceptibility, it is now accepted that MS is an immune-mediated disorder. 1 Although the cause of MS remains to be determined, genetics certainly contributes to disease development. For example, individuals bearing certain HLA haplotypes (e.g. HLA-DRB1*15:01) exhibit an increased risk of developing disease. 3 In addition, sibling studies have determined a statistically significant relationship in rates of MS incidence compared to unrelated individuals. 4 However, these factors cannot account for the increasing incidence of MS, particularly in women, over the past several decades as well as the seminal observation that individuals emigrating from their country of birth before adulthood acquire the relative risk of developing MS as the country to which they relocate. 1 Thus, the impact of how the environment and lifestyle may influence the initiation and/or progression of disease is currently under intense investigation. Although a seemingly infinite number of environmental variables may impact disease in general and MS specifically, the influence of the microorganisms living in or on the body (collectively referred to as the microbiota and their genome being the microbiome) has gained significant traction as a critical, if not central, regulator of human health. 5 Here, we provide a brief introduction into how the microbiota may modulate the severity and progression of MS based on recent studies using patient samples as well as from the most widely used animal model, experimental autoimmune encephalomyelitis (EAE). Of note, these studies should not be confused with investigations into a microbial origin of MS, 1 an important, but distinct area of study that will not be discussed in this review.
commensal organisms), with the number of microbial cells equaling that of human cells. 6, 7 However, this number is mostly based on bacterial counts and is likely an underestimate given that our ability to identify and catalog fungal, protozoan and viral commensal species is only in its infancy. The greatest density of microbes inhabit our intestine and, as a result, has been the most studied microbiota to date. The recent surge of gut microbiome-related studies over the last decade results from the rapid advancement of culturefree, affordable DNA sequencing technologies to identify commensal species within a given microbial community as well as the increased accessibility of germ-free (GF) animals, predominantly mice, amenable to tailored microbial reconstitution. 7 These studies have revealed a fundamental role for the microbiota in immune system development, breakdown of dietary products into soluble metabolites and protection from infection by outcompeting invasive species. 5 In addition to its beneficial functions, a dysregulated gut microbiota (a.k.a. dysbiosis) can have severe consequences on host fitness. Indeed, numerous metabolic and inflammatory disorders in mice such as obesity, diabetes and colitis can be induced simply by the transfer of feces from a diseased animal to a GF recipient. 8 In many cases, disease induction can be explained, at least in part, by the important contribution that the microbiota has on immune system development. GF mice harbor significantly smaller lymphoid organs compared to conventionally raised (CNV) mice as well as significantly fewer inflammatory lymphocytes within the intestine as well as other non-lymphoid tissues. 9 In addition to the direct role that bacterial-derived components such as lipopolysaccharides (LPS) and flagella have on the activation and "conditioning" of the innate and adaptive immune systems via recognition by innate-sensing pathogen recognition receptors, bacteria also breakdown xenobiotics such as dietary products and medications into soluble metabolites that can be used as cellular "fuel" by the host and/or have immune-and neuro-modulatory functions. For example, Clostridia species of the Firmicutes phylum can directly metabolize complex carbohydrates into short-chain fatty acids (SCFA) that promote colonocyte survival, 10 but also induce the differentiation of immunosuppressive CD4+ T regulatory (Treg) cells. 11 In addition, certain spore-forming bacteria have been demonstrated to promote serotonin synthesis by intestinal epithelial cells that regulate the enteric nervous system and stimulate gastrointestinal contractility. 12 More recent studies indicate that metabolite production by specific Bacteroides species stimulate behavioral abnormalities in mice. 13 The potential effects of these soluble factors on the enteric as well as CNS have prompted investigators to examine a potential "gut-brain axis". 14 Related studies have shown that animal models of psychiatric disorders and neurodegenerative diseases such as autism spectrum disorder, Parkinson's disease, and agerelated cognitive decline can all be influenced by alterations of the intestinal microbiota and dysbiosis. 13, 15 Given the impact that the microbiota has on immune cell development and the nervous system, it stands to reason that this host-microbe interaction will significantly affect the course of CNS autoimmune diseases such as MS.
The microbiota and CNS autoimmune disease: lessons from EAE A seminal study by Ivanov et al. demonstrated that GF mice have a significantly reduced number of intestinal interleukin (IL)-17-producing CD4+ T (Th17) cells, an effector population readily found in CNV mice or GF mice colonized with segmented filamentous bacteria (SFB). 16 Previous studies demonstrating that Th17 cells, particularly through their potent production of granulocyte-macrophage colony-stimulating factor (GM-CSF), 17 contribute to the pathogenesis of EAE 18 and are increased in active brain lesions of MS patients 19 provided an important hint that the microbiome may impact disease. Taking advantage of this information, pioneering work from Lloyd Kasper's group demonstrated that mice treated with broad spectrum antibiotics that effectively deplete the gut microbiota were resistant to developing EAE compared to untreated controls. 20 Oral but not parenteral antibiotic treatment correlated with an increased ability of dendritic cells to drive Treg differentiation and an increase in the number of Treg in peripheral lymphoid organs. In addition, transfer from CD4+CD25+ T cells (enriched for Tregs) decreased susceptibility to EAE compared to CD4+CD25+ T cells from untreated animals. 20 These studies were soon corroborated by other groups comparing the incidence of spontaneous and actively induced EAE in GF and CNV mice which also indicated a critical role for the microbiota in disease induction. 21, 22 In all cases, depletion or elimination of the gut microbiota correlated with a decrease in the number of gut and peripheral Th17 cells. 21 Although these initial studies were performed in relatively extreme conditions (i.e. severely decreased or microbe-free mice), they collectively demonstrated a critical role for the gut microbiota in modulating CNS autoimmune disease.
More recently, investigators are taking a more nuanced approach by examining not only how specific bacteria-derived components or metabolites may influence disease outcome but also how modulation of existing complex microbial communities through diet may promote or inhibit encephalitogenic T cell responses. For example, polysaccharide A isolated from the capsule of the human commensal B. fragilis was sufficient to induce anti-inflammatory IL-10+ T cells, decrease the number of Th17 cells and prevent the induction of EAE. 23 Similarly, SCFA (derived from plants and high-fiber whole grains) exclusively broken down by gut microbes promoted the generation of Tregs and decreased the severity of EAE. 24 By contrast, long-chain saturated fatty acids (LCFA, more common in the Western diet) directly promoted the differentiation of both mouse and human Th1 and Th17 in vitro and exacerbated the course of EAE upon dietary LCFA supplementation. 24 In this case, LCFA also induced changes to the gut microbiota and decreased fecal SCFA content. Thus, the effects of LCFA on neuroinflammation are likely through direct and indirect mechanisms. 24 Other dietary components such as tryptophan, an essential amino acid that is metabolized by diverse species of the gut microbiota, are broken down into by-products with potent immunomodulatory effects. 25 Tryptophan metabolism results in production of aryl hydrocarbons that are recognized by the aryl hydrocarbon receptor (AHR) expressed on many host cell types including leukocytes and brain-resident cell types. 26 Although AHR signaling has been shown to promote Th17 differentiation, its actions are both cell-and context-specific and, depending on the acting ligand, can induce Treg cell differentiation. 27 A recent study by Rothhammer et al. 26 demonstrated that AHR expression can be upregulated on both mouse and human astrocytes by type 1 interferons, a first-line treatment for MS patients, and that selective deletion of AHR on astrocytes prevented induction of EAE. They also showed that inclusion of tryptophan or its associated metabolites in the diet reduced EAE severity, whereas inhibiting tryptophan metabolism by the gut microbiota increased disease severity. Importantly, all treatments were performed after the onset of EAE demonstrating the rapid and therapeutic potential for a dietary supplement. 26 Collectively, these studies reveal the complex interconnectedness of diet, microbiota, and the immune system in disease susceptibility.
Connecting our microbial self to MS
Striking results from EAE studies have provided the impetus for examining how commensal organisms may be influencing the pathology of MS. Although only beginning to be examined, 16s ribosomal RNA (rRNA) sequencing of fecal samples from MS patients and healthy controls have revealed notable differences. Jangi et al. 28 found an enrichment of Euryarchaeota and Verrucomicrobia phyla in adults with relapsing-remitting MS (RR-MS) compared to healthy controls. They also observed changes at the genus level. Notably, the relative abundance of the genus Prevotella was decreased in patients that had not received MS drugs. Interestingly, patients treated with either interferon-β or glatiramer acetate exhibited a significantly increased abundance of Prevotella compared to untreated patients. A similar decrease in Prevotella was observed by both Miyake et al. 29 and Chen et al. 30 by examining distinct cohorts of RR-MS patients. Although Jangi et al. did not identify differences in the diversity of the microbiota, none of the patients were experiencing a disease relapse at the time of enrollment. By contrast, Chen et al. found decreased diversity in patients with active RR-MS compared to inactive disease. Although the functional significance of this work remains to be determined, it is noteworthy that LCFA treatment of mice decreases Prevotella species and correlates with enhanced severity of EAE. 24 Another important cohort to consider is patients with pediatric MS. The microbiota of children is less stable than adults making these studies more challenging due to variation, but may provide a window of opportunity to shape disease progression through alteration of commensal microbes. 31 Initial studies have demonstrated an association between bacteria changes at the phylum level with the risk of disease relapse. 32 Identifying differences in the microbiome of these patients may serve as important biomarkers for disease progression and may inform long-term treatment strategies.
While most MS-relevant studies to date have focused on how the gut microbiota acts indirectly on the brain, recent provocative studies indicate that microbes may be acting locally. For example, GF mice have a poorly developed BBB that can be restored following microbial colonization. 33 In addition, 16s rRNA sequencing studies of autopsied brain samples from MS patients and healthy controls have suggested that there may be bacteria in the brain itself, challenging the longstanding belief that it is a sterile organ and presenting the possibility that these brain-resident commensals may be influencing neurological function from within. 34 
Conclusion and opportunities
Evidence for a gut-brain axis is now more compelling than ever. Mechanistic studies using the EAE model have gone beyond proof-of-principle investigations and have begun to dissect how the microbiota can impact the induction and progression of CNS autoimmunity ( Figure 1 ). This work has motivated clinical studies that have revealed differences in the composition of the gut microbiome of MS patients compared to the unaffected population. Although we are still far away from defining an "MS microbiome," the ability to rapidly determine an individual's microbiome through non-invasive measures (i.e. fecal sample collection) could be used as a diagnostic and/or prognostic tool that may inform therapeutic strategies. However, recent insights from shotgun metagenomic sequencing have demonstrated considerable functional overlap between commensal microorganisms. 35 Therefore, it will be important to understand to what extent composition dictates function. To this end, extensive testing of microbial communities from human microbiotas and their products (e.g. toxins, metabolites, etc) will need to be performed to determine their impact on pathogenic or protective immune cell function in vitro as well as following reconstitution of GF mice. Pairing these assays with metabolomic and dietary profiling of stratified patient cohorts and clinical trials of validated targets will hopefully bridge the gap between association and causation. While it is unlikely that the microbiota is the driving factor behind the pathogenesis of MS, it may play a considerable role in the disease outcome of genetically susceptible individuals. The knowledge that the microbiota has diverse effects on host tissues and our rapidly evolving ability to characterize and carefully manipulate microbial communities has led to an exciting time in fundamental and clinical medicine. The time is right to use these resources to make important advances in the treatment and quality of life of individuals living with MS.
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